Benitec Biopharma reports Q2 FY2025 net loss of $7.4M, cash at $78.3M; five patients treated with BB-301 in Phase 1b/2a

Benitec Biopharma Inc.

2024-Q2 EPS reported -$0.76

Net loss $7.4M ($0.33/sh) vs $6.8M ($2.64/sh) year ago; basic shares rose from 2.6M to 22.1M on warrant exercises.
Cash and equivalents $78.3M at Dec 31, 2024, up from $50.9M; includes $39.5M from warrant exercises.
G&A expenses $3.5M (up from $1.8M); R&D flat at $5.1M; total operating expenses $8.6M.
Fifth subject safely treated with low-dose BB-301 in OPMD study; sixth subject expected in Q2 2025.
Interim clinical data to be presented in late-breaking oral at MDA conference on March 19, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.